# Research Progress of A20 in Acute Leukemia: A20 in Acute Leukemia

## TL;DR

This paper reviews the role of A20 in acute leukemia, highlighting its potential as a target for treatment and understanding disease mechanisms.

## Contribution

The paper provides a comprehensive review of A20's role in acute leukemia, offering new insights for targeted therapy.

## Key findings

- A20 is often inactivated, mutated, or deleted in leukemia and lymphoma.
- Lack of A20 impairs immune cell surveillance and promotes tumor immune escape.
- Studying A20's mechanisms may lead to improved treatment strategies for acute leukemia.

## Abstract

Acute leukemia (AL) is a malignant tumor originating from hematopoietic stem
cells. Its outstanding feature is the abnormal proliferation and aggregation of
clonal leukemia cells in bone marrow and other hematopoietic tissues. Although
chemotherapy, targeted immunotherapy and hematopoietic stem cell transplantation
have been widely used in clinic, there are still relapse and refractory cases in
AL patients. Finding new therapeutic targets and screening prognostic molecules
are of great significance for the treatment and prognosis of AL. A20 protein,
also known as tumor necrosis factor α-induced protein 3 (TNFAIP3), is a key
protein that negatively inhibits the activation of nuclear transcription factor
kB (NF-κB) and plays an important role in anti-tumor immune and inflammatory
response. In leukemia and lymphoma, A20 is often inactivated, mutated or
deleted. Lack of A20 can significantly inhibit the surveillance function of
immune cells and mediate tumor immune escape. Therefore, exploring the mechanism
of A20 in AL may have important research value and clinical significance for the
treatment of AL. The purpose of this paper is to review the research progress of
A20 in acute leukemia, and provide new theoretical basis and reference value for
the pathogenesis research and targeted therapy of leukemia.